Signal
Elle, MD Secures C$1.1M to Advance Non-Hormonal Copper Vaginal Ring Clinical Trials
- Category
- · Funding · Global
- Date
- July 27, 2026
- Source
- OVUM
Summary
Vancouver-based Elle, MD Biotechnologies has raised C$1.1 million in pre-seed funding to transition its non-hormonal contraceptive ring, Livv, into human clinical studies. This capital supports a growing demand for effective birth control alternatives that bypass systemic hormonal side effects.
The company works in Maternal & Newborn and Sexual & Reproductive, and this round at Pre-seed ($1.1M) is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.